Serial entrepreneur with 3 successful exits:
Experienced investor with $3M invested into 7 rejuvenation ventures, now part of the quadraScope fund
Active in the industry through participation in studies and serving on the BoD of Healthy Longevity Clinic; donor to key organizations which help with networking
Menachem Abraham is a tech and biotech entrepreneur. His current primary role is co-founder and CEO of Klogenix, an early stage biotech company. In addition to his executive roles, he served as director on the Boards of over a dozen private and public companies in computer networking and telecom. Prior roles include founder and CEO of Mintera Corp. (acquired by Oclaro), president of Lucent Technologies Enterprise Internetworking business unit, founder and CEO of Prominet (acquired by Lucent), and senior vice president and CTO of Chipcom Corporation (public on NASDAQ for five years before it was acquired by 3Com).
Abraham holds bachelor’s and master’s degrees in electrical engineering summa cum laude from the Technion – Israel Institute of Technology and is a graduate of the Stanford/AEA Executive Institute.
Carmela R. Abraham, Ph.D., devoted her entire career to the study of aging and Alzheimer’s disease (AD). She obtained her B.Sc. in Biology at Tel Aviv University and a Ph.D. in Neuroscience at Harvard University. She is Professor Emerita of Biochemistry and Pharmacology & Experimental Therapeutics at Boston University School of Medicine.
Dr. Abraham’s research is both basic and translational. The basic research focuses on understanding the pathologic mechanisms leading to AD and to other neurodegenerative diseases. Dr. Abraham studies ways to protect the nerve cells that die in these diseases and, thus, prevent brain dysfunction. Her group discovered that the Klotho protein, whose levels decrease with age, is neuroprotective, anti-oxidative and anti-inflammatory. In mouse models of AD, multiple sclerosis and ALS, increasing the levels of Klotho improved the outcomes of these diseases. Since higher Klotho levels are associated with better outcomes, Dr. Abraham is exploring various modalities to elevate the Klotho protein.
Based on her findings of 42 years of studying normal aging and AD, she is now focused on finding drugs that would either prevent or alleviate the symptoms of AD and other age-related diseases, such as cancer and kidney disease. She is a co-founder of Klogenix, formerly Klogene, a company which focuses on prevention and treatment of age-related diseases.
Yoseph Linde has over 40 years of experience in the various aspects of the high-tech industry. After graduating from Technion’s faculty of Electrical Engineering (Magna Cum Laude) in 1970, he joined the Israeli Defense Forces where he served 5 years and during that period he received an MSc degree from Tel-Aviv University. In 1975 he left Israel to continue his studies at Stanford University where he received a PhD degree in Electrical Engineering in 1978. He holds seven patents in the areas of communications and computer chip design.
Following his graduation from Stanford, Dr. Linde worked for Codex Corporation (a subsidiary of Motorola) was a professor of Electrical Engineering at Boston University and founded two Massachusetts based high technology companies; Chipcom and LANart. Chipcom had a successful IPO in 1991 and grew to roughly 1,500 employees and $400M of worldwide annual sales before being acquired by 3COM in 1995. Since 2000 he has been a general partner with Jerusalem Global Ventures, a venture capital firm based in Israel (he is no longer involved with new investments). He has served on the boards of numerous technology companies, including two public companies and held many senior positions at high-tech companies.
In the early 1990s Dr. Linde founded and was the first chairman of the New England Technion Alumni Association – the first such an organization in the United States.
Frank is a business strategist and investment consultant with over twenty years of international senior management experience in a variety of industries. Frank holds an M.Sc. in applied economics from the University of Antwerp andcompleted the advanced management program at Harvard Business School. He invested and served on the board of the Managing Partner's last venture, helping with business strategy and analytics. Frank brings proficiency in management consulting, M&A, and investing, offering valuable insights to assist in the growth and exit strategies of our portfolio companies.